Pharma’s Future: Trump’s Influence and Expansion Strategies
February 6, 2026
President Trump highlighted a conversation with the company’s CEO. The company confirms expansion plans already underway.
Recent statements from U.S. President Donald Trump indicate Eli Lilly intends to construct six new facilities within the country. The announcement reportedly occurred during a government meeting at the White House.
Trump stated, “I spoke with the head of Eli Lilly, a fantastic person, exceptionally intelligent, a real star and he told me he is building six plants in the United States, six big plants.”
The pharmaceutical company previously announced an investment of at least $27 billion to establish four plants in the U.S., aiming to strengthen production capacity and supply chain security. Three of these facilities are planned for Alabama, Virginia, and Texas. An Eli Lilly spokesperson clarified to Reuters that, since 2020, the company has announced nine new production sites within the U.S., including the three previously disclosed in 2023.
The Shifting Landscape of Pharma Under Trump
The pharmaceutical industry is navigating a complex environment shaped by the Trump administration’s policies. These include tariff threats, manufacturing investment incentives, and pricing regulations. Companies are actively adjusting to these changes, with negotiation tactics becoming integral to business planning.
As reported in October 2025, pharmaceutical leaders addressed the impact of the administration’s policies during third-quarter earnings reports. Maintaining open communication with the administration has been crucial for companies seeking to avoid scrutiny.
Investment and Reshoring: A New Trend?
Eli Lilly’s expansion plans reflect a broader trend of pharmaceutical companies investing in U.S. Manufacturing. This is likely driven by a combination of factors, including the potential for tariffs on imported goods and incentives to reshore production. AstraZeneca has also announced a significant $15 billion investment in China by 2030, demonstrating a global diversification strategy.
Pricing Pressures and Policy Changes
The Trump administration has focused on reducing drug prices, exploring policies like the “most favored nation” policy. This has created uncertainty for pharmaceutical companies, forcing them to consider supporting these measures or facing potentially more stringent regulations. In May 2025, Trump signed an executive order aiming to lower prescription drug costs by 30% to 80% by referencing international pricing.
The Impact on Research and Development
Recent reports suggest a potential shift in the administration’s approach to research funding. There are indications of cuts to federal science funding, which could impact pharmaceutical research and development. This has raised concerns about the long-term sustainability of innovation in the industry.
Italy’s Pharmaceutical Market and Export
The Italian pharmaceutical market is significantly impacted by these developments, particularly regarding exports to the United States. Italy is a key exporter of pharmaceutical products to the U.S., and changes in U.S. Policy could have substantial consequences for Italian companies.
FAQ
- What is Eli Lilly planning to do? Eli Lilly intends to build six new facilities in the United States.
- What is the Trump administration’s stance on drug pricing? The administration is focused on reducing drug prices through policies like the “most favored nation” policy.
- How are pharmaceutical companies responding to these changes? Companies are adjusting their strategies, investing in U.S. Manufacturing, and engaging in negotiations with the administration.
If you enjoyed this article, stay connected with us on our social channels by following us on:
Or stay up-to-date in the pharmaceutical field by subscribing to our newsletter!
YOU MIGHT ALSO BE INTERESTED IN
In the United States, a new law reforms the role of pharmacy benefit managers
The Conference of Regions has delivered a document to the Minister of Health with proposals on SSN personnel
The telemedicine company Ro is recording a strong increase in customers, driven by the convenience of the oral drug and a more accessible initial price
It is the largest plan ever undertaken by the company in the Asian country and will strengthen production and research.
